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Abstract Xanthine oxidase (XO)-derived superoxide contrib-
utes to endothelial dysfunction in humans and animal models
of hypercholesterolemia (HC). Since L-arginine supplementation
prevents defects in NO signaling, we tested the hypothesis that
L-arginine blunts the inhibitory e¡ect of XO on vascular func-
tion. Acetylcholine-mediated relaxation was signi¢cantly im-
paired in ring segments of HC rabbits, a response that was
associated with an increase in plasma XO activity. L-Arginine
treatment of HC rabbits reduced plasma XO and improved
endothelial function. L-Arginine also modestly prolonged the
lag time for oxidation in isolated lipoprotein samples. These
results reveal that the principal action of L-arginine is to protect
against the XO-dependent inactivation of NO in arteries of HC
rabbits.
' 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Vascular function is compromised under conditions of in-
£ammation and atherogenesis [1,2]. Defects in lipoprotein me-
tabolism and vascular reactivity are fundamental pathological
responses to hypercholesterolemia, with extensive evidence
suggesting that reactive oxygen and nitrogen species play an
important role in the initiation and progression of these le-
sions [3,4]. Blood vessels from atherosclerotic patients and
hypercholesterolemic (HC) animal models exhibit impaired,
endothelium-dependent relaxation [5,6]. Nitric oxide (NO) be-
comes modi¢ed in a hyperlipidemic environment via its reac-
tion with superoxide (Oc32 ), resulting in diminished NO bio-
activity and yielding the potent oxidant peroxynitrite
(ONOO3) [7,8]. Peroxynitrite may promote atherogenesis by
reducing the bene¢cial physiological actions of NO and oxi-
dizing lipoproteins [7,9].
Potential sources of Oc32 in the vascular compartment in-
clude a plasma membrane NADPH oxidase [10], the enzyme
nitric oxide synthase (NOS) when deprived of its substrate
L-arginine [11] and xanthine oxidoreductase (XOR) [12]. Xan-
thine oxidase (XO) is produced from XOR via intramolecular
thiol oxidation or limited proteolysis [13]. In the presence of
O2 and purine substrate, XO yields uric acid and the oxidants
Oc32 and hydrogen peroxide (H2O2). The identi¢cation of XO
in vascular lesions of HC humans suggests that the enzyme
may be a clinically relevant target for the therapeutic treat-
ment of atherosclerosis [14]. This is underscored by ¢ndings
that infusion of the XO inhibitor oxypurinol in humans in-
creases forearm blood £ow in HC, but not hypertensive, pa-
tients [15].
Circulating plasma XO activity is increased in HC rabbits,
with XO capable of speci¢c binding to glycosaminoglycan
(GAG)-rich proteoglycan receptors on vascular cells, resulting
in the concentration of XO at the cell surface [12]. GAG
association also promotes the endocytic incorporation of
bound enzyme, facilitating XO reaction with intracellular pu-
rines and production of reactive oxygen species [16]. Super-
oxide derived from XO also appears to play a role in the
modi¢cation of NO function, since treatment of atherosclerot-
ic blood vessels with the XO inhibitor allopurinol improves
endothelium-dependent relaxation [12,17].
Anti-atherogenic e¡ects of L-arginine have been reported in
humans and animal models [18,19]. Oral treatment with L-ar-
ginine enhances endothelial NO bioactivity in HC humans
[18]. Results of laboratory studies also suggest that chronic
administration of L-arginine to HC animals prevents structur-
al and functional changes in the vasculature [19,20]. The
mechanism underlying the vascular protective e¡ects of L-ar-
ginine has been attributed to an increased availability of sub-
strate for the endothelial NOS isoform. In the current study, it
is revealed that an additional e¡ect of chronic L-arginine ad-
ministration is to limit hepatocellular injury induced by HC
and increases in both plasma XO activity and the production
of Oc32 in the vessel wall of HC rabbits.
2. Materials and methods
2.1. Animals
New Zealand white rabbits (2.5^3.0 kg) were maintained on a
modi¢ed rabbit chow containing 1% cholesterol for 6 weeks prior to
study (HC group). A subgroup of HC rabbits received L-arginine
(2.25%) administered in the drinking water. Age- and weight-matched
rabbits were fed a standard laboratory diet and served as controls in
these studies. All protocols were approved by the Institutional Animal
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Care and Use Committee at the University of Alabama at Birming-
ham and were consistent with the Guide for the Care and Use of
Laboratory Animals (NIH publication 85-23, revised 1985).
2.2. Plasma XO activity
XO activity was detected in plasma samples using high performance
liquid chromatography (HPLC) with electrochemical detection. Prior
to measuring enzymatic activity, endogenous urate was removed by
eluting the sample on a Sephadex G-25 column. Samples were then
treated with oxonic acid (2 mM) to inhibit plasma uricase activity.
Xanthine (75 WM) was then added at 37‡C for 60 min, and XOR
activity assessed by monitoring the production of urate. These reac-
tions were performed in the absence and presence of NADþ (0.5 mM)
and pyruvic acid (5 mM) in order to assess XO and total XOR
activity, respectively. The speci¢city of this detection method for urate
production by XOR was veri¢ed by inhibition of urate formation
following allopurinol addition.
2.3. Plasma cholesterol and alanine aminotransferase measurements
Plasma cholesterol concentration was determined as described by
Allain et al. [21]. Plasma samples were ¢rst treated with cholesterol
esterase to cleave esteri¢ed cholesterol. The free cholesterol in samples
was then oxidized by cholesterol oxidase with the concomitant for-
mation of hydrogen peroxide. Hydrogen peroxide reacts with 4-ami-
noantipyrine and phenol to produce the chromophore quinoneimine.
The absorbance of quinoneimine at 500 nm was monitored photo-
metrically and was directly proportional to cholesterol content in
the sample.
The alanine aminotransferase (ALT) activity of plasma samples was
determined using a modi¢cation of the procedure described by Henry
et al. [22]. ALT catalyzes the transfer of an amino group from L-ala-
nine to K-ketoglutarate, resulting in the formation of pyruvate and
L-glutamate. Pyruvate may then be reduced to lactate in the presence
of lactate dehydrogenase and NADH. ALT activity of plasma sam-
ples is determined indirectly by monitoring the oxidation of NADH at
340 nm. Since all reactants were present in excess, the rate-limiting
step in this reaction is catalyzed by ALT.
2.4. Vessel reactivity studies
Endothelium-dependent and -independent relaxation was moni-
tored in aortic ring segments as described previously [12]. Ring seg-
ments were passively stretched to a tension of 3 g, corresponding to
the optimum range of their length^tension curve. In order to assess
endothelium-dependent, NO-mediated relaxation, aortic rings were
submaximally contracted with phenylephrine (PE) followed by cumu-
lative addition of acetylcholine (ACh). In other experiments, ring seg-
ments were exposed to the endothelium-independent vasodilator so-
dium nitroprusside (SNP). Relaxation responses are reported as a
decrease in vessel tension as a percentage of the pre-existing tone
generated by PE.
2.5. Lipoprotein oxidation studies
L-very low density lipoprotein (L-VLDL) was isolated from plasma
by di¡erential centrifugation. After dialysis against Ca2þ- and Mg2þ-
free phosphate-bu¡ered saline containing NaCl (140 mM), KCl (2.7
mM), Na2HPO4 (8.13 mM), KH2PO4 (1.47 mM) and EDTA (10
WM), the lipoprotein was sterilized by ¢ltration through a 0.22 Wm
¢lter. The oxidizability of puri¢ed L-VLDL samples was monitored to
determine whether L-arginine treatment increased the resistance of
L-VLDL to oxidative modi¢cation. Oxidation of L-VLDL (25 Wg/
ml) was initiated by exposure to 10 WM CuSO4. Lipid peroxidation
results in conjugated double bond formation in polyunsaturated fatty
acids which was monitored spectrophotometrically at 234 nm.
3. Results
The e¡ects of chronic L-arginine treatment on plasma XO
activity, endothelium-dependent relaxation and the oxidizabil-
ity of plasma lipoproteins in HC rabbits were examined. Total
cholesterol was similar in plasma samples obtained from HC
(1682Q 165 mg/dl) and L-arginine-treated (1353Q 230 mg/dl)
HC rabbits, and was elevated in both groups compared to
controls (31Q 4 mg/dl). Vascular reactivity studies, performed
on aortic ring segments of HC rabbits, demonstrated a severe
impairment of ACh-stimulated relaxation (Fig. 1). Maximum
relaxation (Rmax) of ring segments occurred at 1 WM ACh in
HC rabbits and was 8Q 8% compared to 84Q 4% in controls.
While cumulative administration of ACh induced minimal
relaxation in HC rabbits, L-arginine treatment of HC rabbits
blunted the impairment of NO function as demonstrated by a
downward shift in the ACh dose^response pro¢le (Rmax =
69Q 7%; see Fig. 2). Endothelium-independent relaxation in-
duced by cumulative addition of SNP was not di¡erent be-
Fig. 1. Endothelium-dependent and -independent relaxation of rab-
bit aortic ring segments. The vasodilator response of aortic ring seg-
ments from control (b, n=10), HC (F, n=9), and HC rabbits re-
ceiving L-arginine (8, n=7) was tested by cumulative addition of
ACh or SNP. Top panel: ACh-induced relaxation was signi¢cantly
impaired in vessels of HC rabbits. Chronic L-arginine treatment pre-
vented the development of endothelial dysfunction in cholesterol-fed
rabbits. Bottom panel: Endothelium-independent relaxation was
monitored by addition of SNP. No di¡erence in the response to
SNP was noted between groups. Data are meansQS.E.M.
*P6 0.05, signi¢cant di¡erence compared to control and L-arginine-
treated HC rabbits.
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tween groups, supporting that the endothelium is a critical
target of injury in the HC rabbit (Fig. 1).
XO activity was increased approximately four-fold in plas-
ma of HC rabbits (83Q 23 WU/ml) compared to normolip-
idemic, control rabbits (20Q 5 WU/ml) (Fig. 2). Plasma XO
and XOR activities were not statistically di¡erent, suggesting
that the enzyme is present predominantly in the oxidase form.
L-Arginine supplementation of HC rabbits reduced plasma
XO activity (28Q 4 WU/ml) to a level comparable to that ob-
served in control rabbits (Fig. 2). There was a signi¢cant in-
verse correlation between plasma XO and Rmax (r=30.784,
P6 0.00005, n=22) (Fig. 3). These data establish a relation-
ship between increased plasma levels of XO and the impair-
ment of endothelium-dependent relaxation. Since increases in
plasma ALT activity are associated with XO release from the
liver [23], we monitored ALT levels in plasma obtained from
the three treatment groups (Fig. 2). ALT activity was distrib-
uted in a similar manner as XO with a signi¢cant increase in
plasma of HC rabbits (59Q 6 mU/ml) compared to controls
(20Q 3 mU/ml). L-Arginine supplementation of HC rabbits
signi¢cantly reduced circulating levels of ALT (26Q 3 mU/
ml). Plasma levels of ALT and XO were positively correlated
(r=0.419, P6 0.05, n=23).
To further test the e¡ects of L-arginine on vascular redox
activity, we monitored the oxidizability of isolated lipopro-
teins. L-VLDL was isolated from plasma of HC and L-argi-
nine-treated HC rabbits. Oxidation pro¢les were obtained
by exposing the lipid to 10 WM CuSO4 and monitoring
the formation of conjugated dienes spectrophotometrically.
L-VLDL, composed of apolipoprotein and diverse endoge-
nous antioxidants such as K-tocopherol and L-carotene, dis-
plays a lag time prior to the initiation of lipid oxidation that is
used as an index of endogenous antioxidant activity. A short-
er lag time reveals that the antioxidant components of the
particle have been depleted via oxidative reactions and that
the level of endogenous lipid peroxides has increased, thus
enhancing the susceptibility to oxidation. The lag time for
oxidation was modestly prolonged in lipoprotein samples
Fig. 2. Plasma measurements of XO and ALT activity. Top panel:
XO activity was assessed by monitoring urate formation using
HPLC with electrochemical detection. XO activity was elevated ap-
proximately two-fold in plasma from HC rabbits (n=9). L-Arginine
treatment of HC rabbits (n=7) reduced plasma XO activity to levels
comparable to those of control rabbits (n=10). Middle panel: Since
ALT is a marker for hepatic injury and is associated with the he-
patic release of XO into the circulation, plasma enzyme activity was
monitored. L-Arginine treatment caused a signi¢cant reduction in
ALT activity in HC rabbits suggesting a hepatoprotective e¡ect of
L-arginine. Bottom panel: There was a positive correlation
(r=0.419, P6 0.05, n=23) between plasma XO and ALT activities.
Data are meansQS.E.M. *P6 0.05, signi¢cant di¡erence compared
to control and L-arginine-treated HC rabbits. Fig. 3. Relationship between plasma XO activity and relaxant ca-
pacity of isolated aortic ring segments. Data points depict responses
of control (b, n=10), HC (F, n=6) and L-arginine-treated HC rab-
bits (8, n=6). Negative values on the abscissa re£ect contractile re-
sponses to ACh in HC rabbits.
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from L-arginine-treated HC rabbits (95 Q 10 min, n=8,
P6 0.05) compared to untreated HC rabbits (62Q 6 min,
n=7).
4. Discussion
Endothelial dysfunction is a hallmark of atherosclerosis in
both animal models of hypercholesterolemia and humans
[2,5]. The enzyme XO binds to the endothelium in the HC
rabbit, may be expressed at greater levels in vascular cells and
is a source of both of Oc32 and H2O2 [12]. In support of the
hypothesis that oxidants derived from XO contribute to vas-
cular dysfunction, several studies showed that the XO inhib-
itor allopurinol improves endothelial function in experimental
models of cardiovascular disease [12,13,24]. Other data sug-
gest that the development of endothelial dysfunction in hu-
mans and animal models of atherosclerosis is due to a deple-
tion of L-arginine substrate, the precursor for NO synthesis
[2,25], which may also account for the diminished vasodilator
response of isolated vascular preparations to calcium-mobiliz-
ing agonists such as ACh. While chronic dietary supplemen-
tation of HC rabbits with L-arginine has been shown to re-
store endothelium-dependent relaxation [20], acute treatment
of isolated tissues with L-arginine has shown mixed e¡ects on
the restoration of endothelial NO production, suggesting that
substrate availability may not be a rate-limiting factor
[7,26,27]. An additional vasoprotective mechanism proposed
for L-arginine is the stimulation of insulin release that in turn
directly promotes vasorelaxation by enhancing NO formation
[27]. Herein, it is reported that chronic treatment of HC rab-
bits with L-arginine signi¢cantly restores endothelium-depen-
dent vasodilator function in arteries of HC rabbits, with an
L-arginine-induced reduction in plasma XO and its oxidizing
products strongly correlating with improved ACh-mediated
relaxation. While direct measurements of O32 were not carried
out in the current studies, our previous ¢ndings show that
increases in plasma XO are associated with enhanced vascular
Oc32 generation [12], supporting that the restoration of endo-
thelium-dependent relaxation in L-arginine-treated HC rabbits
is due to diminished reaction of Oc32 with NO, and thus less
ONOO3 production.
Numerous studies have used LDL oxidation measurements
as a surrogate endpoint to show that speci¢c therapeutic in-
terventions decrease atherosclerosis. L-Arginine treatment did
not alter plasma total cholesterol in HC rabbits but was
associated with a modest reduction in the oxidizability of
L-VLDL, suggesting that L-arginine indirectly preserves en-
dogenous levels of antioxidant molecules in lipoproteins
and/or limits the formation of pre-formed lipid peroxides
[28]. The increase in lag time was approximately 33 min in
L-arginine-treated HC rabbits, and it is not clear whether such
a small e¡ect can signi¢cantly alter the progression of athero-
sclerosis. In contrast to the e¡ects of L-arginine, chronic treat-
ment of HC rabbits with the antioxidant probucol yields a lag
time for LDL oxidation that is increased more than 860 min
over control [29]. Our results therefore suggest that bene¢cial
e¡ects of L-arginine in the prevention of endothelial dysfunc-
tion in hypercholesterolemic rabbits are largely independent
of the susceptibility of L-VLDL to oxidation.
In the current study, the enhanced antioxidant activity of
L-arginine was associated with the limitation of hepatocellular
release of ALT and XO and improvement of endothelium-
dependent vasodilator function. The liver is an important
source of circulating XO under pathologic conditions. It is
hypothesized that a major protective e¡ect of L-arginine under
conditions of hypercholesterolemia is to minimize hepatic in-
jury and concomitant XO release into the circulation. In sup-
port of this precept, L-arginine treatment induced a reduction
in plasma levels of ALT, a hepatic enzyme associated with XO
release from the liver [30]. Results of other studies support a
hepatoprotective role for L-arginine. In this regard, it was
shown that L-arginine infusion reduces liver injury associated
with ischemia^reperfusion [31]. The protective e¡ect of L-argi-
nine was reversed by NOS inhibitors, implicating enhanced
NO synthesis as an important component of this response
[31]. The mechanism(s) underlying the protective e¡ect of
L-arginine in our model may thus involve a reduced hepato-
toxic response to elevated cholesterol in the rabbit. Chronic
L-arginine treatment may also improve hepatic blood £ow by
an NO-dependent mechanism, thereby reducing regional is-
chemic injury associated with cholesterol deposition. A reduc-
tion in XO release from the liver and circulating levels of the
enzyme would then be expected under these conditions. We
previously reported an increase in circulating and vessel-
bound XO in SCD patients and knockout-transgenic SCD
mice [32]. This response was associated with an increase in
the hepatocellular release of ALT [17] and was viewed to be a
consequence of episodes of hepatic hypoxia^reoxygenation in
SCD patients. Hepatic XO release and its subsequent binding
to vascular elements may thus represent a common mecha-
nism for tissue injury in atherosclerosis, SCD and possibly
other vascular diseases. In summary, our results show that
an important response to chronic L-arginine treatment in
HC rabbits is the improvement of vasodilator function via a
mechanism that is associated with reduced circulating levels of
XO.
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